Details of the Drug Reposition

General Information of This Drug (ID: DMC50VB)

• Drug Name: Orforglipron (DMC50VB)
• Synonyms: Orforglipron; LY3502970; 2212020-52-3; CHEMBL4446782; LY-3502970; 3-[(1S,2S)-1-(5-[(4S)-2,2-dimethyloxan-4-yl]-2-{(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carbonyl}-1H-indol-1-yl)-2-methylcyclopropyl]-1,2,4-oxadiazol-5(4H)-one; 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one; V6G; orforglipron [INN]; ORFORGLIPRON [USAN]; OWL833; SCHEMBL21175277; GTPL12175; 7ZW40D021M; EX-A7751; BDBM50514045; AKOS040733262; GLP-1 receptor agonist 1;Orforglipron; MS-31635; HY-112185; CS-0043632; 1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcyclopropyl]-; 3-[(1S,2S)-1-({2-(4-fluoro-3,5-dimethylphenyl)-3-({3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-5-[(4S)-2,2-dimethyloxan-4-yl]-1H-indol-1-yl}-2-methylcyclopropyl]-5-oxo-1,2,4-oxadiazol-4(5H)-ide
• Drug Type: Small molecule

Information on Drug Reposition of This Drug

1 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Obesity	DIS47Y1K	5B81	Phase 3	[1]

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Type 2 diabetes	DISJ9M77	5A11	Phase 2	[2]

References

• [1] ClinicalTrials.gov (NCT05869903) A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1). U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT05048719) A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus. U.S.National Institutes of Health.